Titan Biotech has officially unveiled plans for its inaugural 1:4 bonus share issuance. This move signifies that existing shareholders will receive one new equity share for every four currently held, marking a significant milestone for the company.
The announcement follows an exceptional run on the stock market. The firm has delivered stellar returns, boasting a surge of over 200% throughout the past twelve months and maintaining strong momentum with 100% growth recorded in 2026 alone.
Key investor takeaways:
- The bonus remains subject to formal shareholder approval.
- The move is designed to enhance liquidity and reflect long-term value creation.
- Investors should monitor official record dates to ensure eligibility for the payout.
As the company transitions into this new phase, market analysts are closely watching how the increased float will influence trading activity in the coming weeks.
